Dr Michael Antoniou

Current projects

Advancing plasmid and lentiviral vectors incorporating HNRPA2B1-CBX3 and Rps3 UCOEs for improved protein therapeutic biomanufacturing and for targeting a wide range of tissues including the haematopoietic system, CNS, liver and muscle within a gene therapy context.
Development of novel lentiviral vectors for gene therapy of the haemoglobinopathies (thalassaemia and sickle cell disease).
Investigating the endocrine disruptive capability of low, environmentally relevant doses of pesticides and other chemical pollutants.